The JNK-MCL-1 axis contributes to the anticancer activity of MT189. 
Introduction
In recent years, colchicine-binding-site-targeted tubulin inhibitors have become a promising type of anticancer drugs with several of them entering into clinical trials (1) .
We previously constructed a combinatorial library of 6H-Pyrido[2',1':2,3]imidazo [4,5-c] isoquinolin-5(6H)-ones (2) from which two new tubulin inhibitors, MT7 and its structurally-modified antiproliferation-activity-improved derivative MT119, were obtained. Both cause microtubulin depolymerization, persistent M phase arrest and apoptosis. MT119 was confirmed to bind to the colchicine-site on tubulin (3) (4) (5) .
Although both produce potent in vitro antiproliferative effects and overcome tumor multidrug resistance (MDR), they did not show obvious in vivo anticancer activity. In considering their structural novelty and potential new modes of action, we put persistent efforts into further structural optimization on MT119. Finally, we acquired a new colchicine-site binder 2-(6-fluoro-3-((4-methoxybenzyl)amino)imidazo [1,2-α] pyridin-2-yl) phenol (designated as MT189) (Suppl. Fig. 1 ).
Tubulin inhibitors, including those targeting the colchicine site, can disrupt cellular microtubulin assembly, followed by persistent M arrest and subsequent apoptosis. Both M arrest and apoptosis contribute to their anticancer effects (3, 4, 6) .
Besides, other mechanisms of action and/or signaling pathways might be involved.
We previously found that the naturally occurring colchicine-site binder pseudolaric acid B (7) could activate the JNK-c-Jun-hypoxia inducible factor 1α (HIF-1α) signaling axis to inhibit angiogenesis and overcome tumor MDR (8, 9) . JNK can be activated by its upstream MAP kinase kinase kinases (MAP3Ks; at least 14 kinases, . Both MKK4 and MKK7 phosphorylate JNK but MKK4 also activates p38 (10) . However, whether the new colchicine-site binder MT189 could also activate JNK and if so, which upstream kinases are involved, remain to be clarified. In addition, the relationship between microtubulin disruption, mitotic arrest and JNK activation triggered by MT189 needs investigating.
Besides c-Jun, JNK has many other substrates, one of which is the antiapoptotic protein MCL-1 (11) . MCL-1 is a member of the BCL-2 protein family. It promotes survival via inhibiting apoptosis by suppressing proapoptotic proteins BAX and BAK (11, 12) . Antitubulin agents paclitaxel and vincristine that bind to the taxane site and the vinca site on tubulin, respectively, have been shown to cause phosphorylation of MCL-1 via JNK, which subsequently leads to ubiquitination-mediated MCL-1 degradation (11) . So it is intriguing whether the colchicine-site binder MT189 also affects MCL-1 via JNK and if so, what effects will be caused on its anticancer activity.
In this study, we first examined the effects of MT189 on microtubulin dynamics, cell cycle and apoptosis to determine whether it retains the characteristics of its parental compound MT119. Next, its in vitro and in vivo activities against tumor cells were measured. After that, we further tested the impacts of MT189 on MCL-1 and the JNK signaling pathway. Finally, whether MT189-induced microtubule disruption is directly related to its activation of the JNK signaling axis was explored. 
Materials and Methods
on
Proliferation inhibition assays
Sulforhodamine B (SRB) assays were done as reported previously (4) 
Western blotting
Western blotting was performed as previously described (8) .
Immunofluorescence-based laser confocal microscopy
Cells were seeded on glass coverslips, cultured for 24 h and treated with appropriate agents for the indicated time. Then, the cells were fixed for 15 min with 4% paraformaldehyde, permeabilized for 5 min with 0.2% TritonX-100, blocked with 3% bovine serum albumin for 15 min, incubated with the primary antibody for 1 h, and stained with fluorescence-conjugated secondary antibody for 1 h. Finally, after being counterstained with DAPI, the cells were imaged under an Olympus confocal microscope (Olympus, Tokyo, Japan).
In vitro tubulin polymerization assays
Tubulin was purchased from Cytoskeleton (Denver, CO). In vitro tubulin polymerization was assessed by the turbidity assay as previously described (4).
Cellular microtubulin polymerization assays
The cells were treated with the given agent and harvested in the lysis buffer (100 mM PIPES pH6.9, 1 mM EGTA, 1 mM MgCl 2 , 30% glycerol, 5% DMSO, 1% NP-40, 5 mM GTP and protease inhibitors). The polymerized tubulin fraction (precipitate) and the soluble tubulin fraction (supernatant) were separated by centrifugation at 180,000 g at 37°C for 1 h. Finally, α-tubulin from equal aliquots of the polymerized tubulin fraction and the soluble tubulin fraction was determined by Western blotting (4).
Tubulin-site competitive binding assays
Tubulin (3 μM) was incubated with the tested agents at 37°C for 1 h. Then colchicine or BODIPY FL-vinblastine was added to the final concentration of 3 μM.
The fluorescence was determined after 30 min at 37°C with a PerkinElmer fluorometer (4, 15) .
Cell cycle assays
Cells were seeded into 6-well plates, cultured overnight and treated with MT189 for the indicated time. In order to examine the reversibility of cell cycle arrest, the cells treated with 0.2 μM MT189 for 12 h were washed with medium 3 times and then incubated in drug-free full medium for the indicated time. Cells were then harvested and washed with PBS, fixed with pre-cooled 70% ethanol at 4°C. Staining went along in PBS containing 40 μg/ml RNase A and 10 μg/ml propidium iodide in the dark for Biosciences, Franklin Lakes, NJ) and analyzed using the CELLQUEST software (BD Biosciences, Franklin Lakes, NJ).
TUNEL assays
Cells were seeded into 6-well plates, cultured overnight and treated with MT189.
Then, cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% TritonX-100 and washed with phosphate-buffered saline (PBS). TUNEL assays were performed with an in situ cell death detection kit (Roche Applied Science, PA) according to the manufacturer's instructions.
Annexin V-FITC apoptosis detection
Cells were seeded into 6-well plates, cultured overnight and treated with different agents. Then, cells were harvested, washed and stained by using the AnnexinV-FITC apoptosis detection kit (Beyotime, Shanghai, China). Fluorescence of the cells was determined immediately by flow cytometry (BD Biosciences, Franklin Lakes, NJ).
Mitochondrial membrane potential detection
Then, cells were harvested, washed and stained by using JC-1 kit (Beyotime, Shanghai, China). Fluorescence of the cells was determined immediately by flow cytometry (BD Biosciences, Franklin Lakes, NJ).
Plasmid transfection
The plasmid expressing wild-type MCL-1 (#25392) was obtained from Addgene, Cambridge, MA. The transfection was conducted as reported previously (8) . We previously reported that MT7 (3) and its efficacy-improved derivative MT119 (4) were new colchicine-site-binding tubulin inhibitors. Both are easy to be synthesized and MT119 is also active even in multidrug resistant tumor cells.
Disappointingly, however, both of them lack in vivo anticancer activities, possibly due to their relative weak bioactivity. So based on MT119, continuous structural optimization has been carried out. Among other efforts, one de-construction approach was taken to break the tetracyclic ring of MT119 to a new intra-molecular hydrogen bonding scaffold (iMHB scaffold). A phenolic group was introduced to the alpha position of phenyl ring to form a pseudo-ring through the intra-molecular hydrogen bonding between the imidazole nitrogen and the phenolic hydrogen atom to lock the planar conformation and to mimic the original tetracyclic ring space in MT119 (Suppl. To characterize MT189, we tested whether it retained the property of MT119 in impairing microtubule assembly and arresting cell cycle. The classical microtubule stabilizer paclitaxel promoted microtubulin polymerization as expected. In contrast, MT189 inhibited tubulin polymerization in a concentration-dependent manner, similar to the microtubule destabilizer colchicine (Fig.1A) . In addition, MT189 competitively (Fig.1B) . The data indicate that MT189 binds to tubulin at the colchicine site rather than the vinblastine site.
In interphase cells, microtubules radiate from the microtubule-organizing center located at the centrosome in the cytoplasm, involved in the maintenance of cell shape (16) . The treatment of SMMC-7721 cells with MT189 resulted in scattered tubulin staining and long microtubule fibers could rarely be observed in the cell (Fig.1C) .
Moreover, MT189-triggered microtubule depolymerization occurred very early (within 0.5 h) and then persistently progressed (Suppl. Fig.3A ). In addition, MT189
caused an increase in the free microtubulin fraction (supernatant) and simultaneously a decrease in the polymerized microtubulin fraction (precipitate) in the cell although the levels of total tubulin kept unchanged (Fig.1D) . The data indicate that MT189 can disrupt the microtubule assembly by inhibiting tubulin polymerization in the cell.
MT189 was further shown to lead to a typical, reversible G2/M arrest in SMMC-7721 cells in a time-and concentration-dependent manner (Fig.1E and Suppl. Fig.3B ). The enhanced levels of the two mitotic markers MPM-2 and Ser10-phosphorylated histone 3 (17) (Fig.1F ) in MT189-treated SMMC-7721 cells indicated that MT189 caused cell cycle arrest in M rather than G2 phase. During mitosis, cellular microtubules are normally assembled into bipolar mitotic spindles to guarantee equal segregation of the chromosomes (18, 19) (Fig.1G) . However, MT189 (Fig.1G) . The data indicate that MT189 interferes with mitosis progression by disrupting mitotic spindle assembly.
All the above results show that MT189 retains the property of its parental compound MT119 in impairing microtubule assembly (4).
MT189 induces intrinsic apoptosis and exerts enhanced in vitro and in vivo activities against tumor cells.
Persistent mitotic arrest caused by microtubule depolymerization has been demonstrated to trigger apoptosis (20, 21) . So we investigated whether and how MT189 induced apoptosis. The treatment with MT189 led to a progressive increase in apoptosis in a time-dependent manner in SMMC-7721 cells ( Fig.2A) . MT189 also caused apparent loss of mitochondrial membrane potential (MMP) in these cells in a concentration-dependent manner (Figs. 2B and 2C). Apoptosis can roughly be classified into two types: caspase-8-mediated extrinsic apoptosis and caspase-9-initiated intrinsic apoptosis (22, 23) . MT189 caused the cleavage of PARP, caspase-3 and caspase-9 rather than caspase-8 in a time-and concentrationdenpendent manner (Fig.2D) , indicating that it mediates mitochondria-involved caspase-9-initiated intrinsic apoptosis. 
reduce the levels of MCL-1 protein in a time-dependent manner, but did not obviously change the protein levels of the other tested members (Fig.3A) . Moreover, the caspase inhibitor Z-VAD-FMK did not prevent MCL-1 reduction but did prevent PARP cleavage induced by MT189 (Suppl. Fig.5A ). The results suggest that MCL-1 might be associated with MT189-induced apoptosis.
To clarify whether MT189-induced MCL-1 reduction contributes to its in vitro proliferation-inhibitory activity, we compared its effect on the levels of MCL- (Fig.3B ). The treatment with MT189 for 24 h led to reduction of MCL-1 protein levels in a concentration-dependent manner in all three relative sensitive cell lines, but did not obviously changed the levels of MCL-1 protein in the insensitive cell lines (Fig.3B) .
Nevertheless, MCL-1 protein levels in DU145 cells also decreased in a concentration-dependent manner when the treatment time with MT189 was prolonged to 48 h (Suppl. Fig.5B ). However, MT189 induced apparently less apoptosis in DU145 cells than in HeLa cells at the same conditions (Suppl. Fig.5C ). Moreover, the ectopic overexpression of MCL-1 attenuated (but did not abolish) the cleavage of caspase-9, caspase-3 and PARP (Fig.3C ) and the loss of viable cells (Fig.3D) 
(siMCL-1)-transfected cells (Figs.3E and 3F ). These results indicate that MT189-induced apoptosis is potentiated by MCL-1 reduction in the cells, which contributes to its in vitro proliferation-inhibitory activity.
However, MT189 did not lower the mRNA level of MCL-1 (Suppl. Fig.6 ). But the proteosome inhibitor MG132 could rescue MCL-1 protein reduction by MT189 (Fig.3G) . Moreover, MT189 apparently increased the ubiquitination of MCL-1 protein (Fig.3H) . The data reveal that MT189 promotes the degradation of MCL-1 protein via the ubiquitin-proteosome pathway.
MT189-mediated JNK activation causes degradation of MCL-1 protein.
The MAPK kinases JNK and p38 have been shown to participate in the regulation of the MCL-1 protein stability (11, 25, 26) . MT189 was revealed indeed to increase their activated (phosphorylated) forms but not to change their total proteins levels ( Fig.4A) . However, it was the JNK inhibitor SP600125 but not the p38 inhibitor PD169316 that prevented the MT189-mediated Ser159/Thr163 phosphorylation and degradation of MCL-1 protein in SMMC-7721 cells (Fig.4B,   upper) . Consistently, SP600125 rather than PD169316 partially reversed the cleavage of caspase-9, caspase-3 and PARP (Fig.4B, lower) , apoptosis (Figs.4C and 4D ) and the loss of viable cells (Fig.4E) induced by the treatment with MT189 in SMMC-7721 cells. Moreover, p-JNK was shown to be colocalized with both MCL-1 and p-MCL-1 in the MT189-treated SMMC-7721 cells (Fig.4F) . The results indicate that MT189 mediates JNK activation, which leads to MCL-1 phosphorylation that facilitates its ubiquitination-driven degradation. 
MT189 mediates JNK activation via the MEKK1/TAK1-MKK4 pathway.
The JNK inhibitor SP600125 also inhibits CDK1 (27) . So we used another JNK inhibitor JNK-IN-8 (28) and a CDK1 inhibitor RO3306 (29) (30) (31) . The result showed that the MT189-mediated MCL-1 degradation could be reversed only by the JNK inhibitors but not by the CDK1 inhibitor (Fig.5A) . Additionally, both JNK and CDK1 were reported to mediate phosphorylation of the antiapoptotic protein BCL-2 (32-34).
However, the CDK1 inhibitor RO3306 did not affect the MT189-mediated increase in the phosphorylation level of BCL-2 (Fig.5B) . Moreover, either overexpression or silence of MCL-1 did not change the cell cycle arrest induced by MT189 (Fig.5C ).
These data strengthen the evidence supporting the conclusion that the MT189-mediated JNK activation rather than the mitotic arrest-related CDK1 activation causes the increased phosphorylation levels of MCL-1 followed by its ubiquitination-driven degradation.
The next question is how MT189 mediates JNK activation. Either JNK or p-JNK did not appear in the immunoprecipitated α-tubulin complexes in the control or MT189-treated SMMC-7721 cells (Fig.5D ). In the control cells, both JNK and p-JNK were observed mainly in nuclei, but they were not revealed to be colocalized with tubulin. The treatment with MT189 did not change this feature of either JNK or p-JNK, although it increased the levels of p-JNK (Suppl. Fig.7 ). The data suggest that there is no direct interaction between tubulin and JNK, and JNK phosphorylation followed by the treatment with MT189 must be caused by some kinase(s).
JNK has been shown to be activated via MAP kinase kinase kinases (MEKK1 In this study, we found that MT189, a new optimized derivative of MT119 (4) retained its property in impairing microtubule assembly by depolymerizing microtubules via binding to the colchicine site, leading to M arrest and inducing apoptosis. MT189 showed significantly improved in vitro proliferation-inhibitory activity and direct killing of MDR tumor cells. However, its in vivo anticancer activity is still limited. MT189 has very low solubility in water, and thus it was administered by intraperitoneal injection rather than by intravenous injection (as taxol) in this study.
When administered at 100 mg/kg/d once a day to nude mice, MT189 caused tumor growth inhibition by 35.9% on day 14. At this time-point, all tested animals were alive and showed no obvious loss of the body weight. However, on day 17, the animals began to die, and till day 21, among 8 tested animals in the MT189 group, only one was still alive. Therefore, demonstrating what are the primary toxicity organs and the related toxicity mechanisms of MT189 is critical for our future work.
MT189 binds to cellular microtubules via the colchicine site, leading to rapid microtubule depolymerization (within 0.5 h) followed by persistent M arrest and subsequent apoptotic induction. In addition, MT189 also relieves the apoptosis suppression of the antiapoptotic protein MCL-1 by promoting its degradation via the ubiquitination-proteosome pathway, which potentiates its apoptotic induction and thus its anticancer effects. Consequently, persistent mitotic arrest, apoptosis and MCL-1 degradation collectively contributes to the anticancer activity of MT189 (Fig.5F ). (11), CDK1 (12, 34) and NOXA (35, 36) . However, whether colchicine-binding-site tubulin inhibitors elicit similar effects remains to be clarified. In this study, we demonstrated that the colchicine-site-targeted tubulin inhibitor MT189 sequentially activated MEKK1/TAK1, MKK4 and JNK (Fig. 5E) . Activation of JNK caused phosphorylation of MCL-1 that facilitated its ubiquitination and subsequent degradation. However, we did not observe that microtubulin (either intact or disrupted) was colocalized with JNK, MEKK1 or TAK1 or their respective phosphorylated equivalents. The result suggests that MT189 could mediate the activation of the MEKK1/TAK1-MKK4-JNK pathway via unknown intermediary kinase (s) in a microtubulin depolymerization-dependent fashion (Fig. 5F ).
MCL-1 is
In fact, various extracellular stimuli such as cytokines and protein synthesis inhibitors can stimulate phosphorylation of JNK (37) . Many other anticancer agents with different molecular targets or mechanisms of action can also lead to the activation of this pathway (10, 37, 38) . Notably, detailed time-effect analyses showed that taxol, a microtubulin-polymerization-promoting anticancer agent, activated JNK at early stages (30 min) (37, 38) , just as MT189 did (0.5 h; Fig. 5E ). All the lines of evidence suggest that the depolymerization of microtubules is an essential factor for JNK activation. JNK has multiple substrates and is involved in extensive physiological and pathophysiological processes and therapeutic responses (8, 10, (39) (40) (41) . Apparently, it is deserved to put continuous efforts into demonstrating which unknown factor(s) and how they mediate JNK activation. 23 We have already shown that in MT189-treated cancer cells, microtubule depolymerization causes both M arrest (Figs. 1E, 1F and 5F) and JNK activation following with MCL-1 degradation (Figs. 4, 5E and 5F ). Notably, however, both microtubule depolymerization and JNK activation took place at very early stages (0.5 h; Fig. 5E and Suppl. Fig. 3 ), but M arrest occurred at relatively late stages (3 h or later; Figs. 1E and 1F) in those cells. Moreover, both tested JNK inhibitors, but not the CDK1 inhibitor, could reverse MCL-1 degradation (Fig. 5A) ; the CDK1 inhibitor did not prevent the increase in the MT189-induced BCL-2 phosphorylation (Fig. 5B) although CDK1 was reported to mediate phosphorylation of BCL-2 (34); and the changes in MCL-1 protein expression did not affect the MT189-induced M arrest (Fig.5C ). Additionally, MT189 was shown to mediate JNK activation via the MEKK1/TAK1-MKK4 pathway. Therefore, JNK activation is independent of M arrest in MT189-treated cancer cells (Fig.5F ).
Together, this study presents a new tubulin inhibitor MT189 with anticancer activity and retaining the colchicine-site-targeted characteristics of its parental compound MT119. Besides its mitosis arrest and apoptosis induction, we show that relief of apoptosis suppression due to MCL-1 degradation subsequent to the activation of the MEKK1/TAK1-MKK4-JNK pathway potentiates apoptotic induction of MT189. We believe that demonstrating how to activate this pathway is helpful to further understand the mechanisms of action of MT189 and thus to promote the optimization and development of its new derivatives. 
